ACE-031 development halted over vascular side effects, worth revisiting?
Posted by restlessemma in Research & News - 4 points, 5 comments.
Was reading through the ACE-031 profile on here (/peptides/ace-031) and the halted development for DMD got me thinking. The bleeding side effects, epistaxis, gum bleeding, telangiectasia... Those are pretty concerning signals imo. The fact that they pulled the plug on a myostatin ligand trap because of vascular effects makes me wonder if that is just an ACE-031 specific issue or something inherent to blocking the ActRIIB pathway broadly.
I track my bloodwork pretty regularly and the thing that always jumps out at me with these anabolic brakes is how interconnected the TGF-beta family is. You cannot just block myostatin without touching activin and GDF-11, and those ligands do stuff in vascular tissue too. So when people get excited about myostatin inhibitors for muscle growth I always want to ask... At what cost to other systems?
The lean mass and bone density data looked promising for sure. But the telangiectasia and bleeding risk would scare me off personally, even in a research context. Has anyone here looked into whether newer myostatin approaches avoid the vascular bleed-through, or is this just the trade-off you accept with this pathway? Genuinely curious where the research has gone since the halt.
Comments
- sleep_coastal: Anecdotally I looked into ACE-031 years ago and the bleeding signals were enough to make me nope out pretty fast. The telangiectasia thing is not subtle, that is visible vascular remodeling, not some rare idiosyncratic reaction. My read on it is the ActRIIB trap approach is inherently messy because you are catching a broad net of ligands, not just myostatin. Activin A alone has real roles in endothelial integrity. So when you block that pathway you get leaky vasculature as a feature, not a bug.
- restlessemma: Yeah the telangiectasia being visible vascular remodeling is exactly what got me hung up on it too. That is not something you can hand-wave away as a rare adverse event, eh. Your point about activin A and endothelial integrity makes a lot of sense to me... Blocking the whole ActRIIB net is bound to have downstream effects you cannot really predict from animal models. Did bimagrumab actually end up looking cleaner in practice though? I know it was more selective but I vaguely recall it still had
- fasted_scientist: Ngl, that makes sense but I’d like to see the actual bleeding rates from the bimagrumab trials before calling it a clean win. Do you have those numbers handy? For me the signal still feels tied to how much activin you’re blocking.
- restlessemma: I do not have the exact bleeding rates for bimagrumab on hand, but I can try to dig through the trial data and post them if I find them. I agree that the amount of activin blockade is the real variable here imo. It seems like a fine line between gaining lean mass and causing telangiectasia... I would be curious if there is a specific threshold where the vascular signals start to outweigh the benefits.
- fasted_scientist: Ngl I reckon that threshold is the million dollar question here. If you can find those bimagrumab numbers that would be brilliant. I am a bit skeptical that we can find a safe window if the mechanism itself is messing with vascular integrity. It seems like a massive gamble to try and walk that line without more data on the specific activin levels.
Community discussion - research and educational context only. Not medical advice.